Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:57:11 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Optomed Q3 - Solid quarter from both the software and devices segment

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Optomed Q3 - Solid quarter from both the software and devices segment

2023-11-06 07:44:00

Redeye provides an update in relation to Optomed’s Q3 2023 report. The report came in better than expected, with sales of EUR4.2m (EUR3.7m) and a solid positive cash flow from operating activities. Furthermore, we assume that the additional data has not been sent in yet to the FDA. We now expect a potential FDA approval in early 2024 and view this as a major trigger for the share. Moreover, we only make minor estimate changes; however, we increase our WACC, which renders in an updated fair value range, including a new base case of EUR7.5 (8).

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/